Optimised Prime: A Transformative RNA-LNP Vaccine Composition that Scales
Time: 9:30 am
day: Day One AM
Details:
- LNP formulation and physicochemical characteristics with both messenger RNA (mRNA) and self-amplifying RNA (saRNA)
- In vivo immunogenicity of RNA-LNP vaccines against influenza A and SARS-CoV-2
- Overcoming scale-up and process development challenges in vaccine development
